

# Sandra Santarossa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10193442/publications.pdf>

Version: 2024-02-01

12  
papers

175  
citations

1684188

5  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
2	Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. <i>BMC Research Notes</i> , 2012, 5, 482.	1.4	39
3	A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi's Sarcoma. <i>Drug Safety</i> , 1999, 20, 403-425.	3.2	26
4	Solitary meningeal recurrence in a patient with transitional cell carcinoma of the bladder with locally bulky disease at presentation. <i>Journal of Neuro-Oncology</i> , 1997, 35, 141-143.	2.9	11
5	Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report. <i>BMC Research Notes</i> , 2014, 7, 589.	1.4	9
6	Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients. <i>European Journal of Cancer</i> , 1995, 31, 1718.	2.8	4
7	Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8945-8950.	2.0	4
8	Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. <i>Oncotarget</i> , 2018, 9, 15340-15349.	1.8	4
9	Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients. <i>European Journal of Cancer</i> , 1994, 30, 918-920.	2.8	3
10	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A G.I.O.N. trial. <i>Journal of Clinical Oncology</i> , 2017, 35, e16081-e16081.	1.6	1
11	Weekly cabazitaxel in elderly patients (EP) with metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel treatment: WeCabE, a phase II study. <i>Journal of Clinical Oncology</i> , 2018, 36, 300-300.	1.6	1
12	Severe ulcers from an unconventional therapy against AIDS. <i>Aids</i> , 1995, 9, 536.	2.2	0